S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?

Krystal Biotech (KRYS) Stock Price, News & Analysis

$177.93
+0.73 (+0.41%)
(As of 03/28/2024 ET)
Today's Range
$175.99
$180.12
50-Day Range
$108.01
$179.35
52-Week Range
$77.10
$189.97
Volume
392,908 shs
Average Volume
399,658 shs
Market Capitalization
$5.03 billion
P/E Ratio
2,224.40
Dividend Yield
N/A
Price Target
$157.67

Krystal Biotech MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
11.4% Downside
$157.67 Price Target
Short Interest
Healthy
7.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.54mentions of Krystal Biotech in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$6.54 M Sold Last Quarter
Proj. Earnings Growth
129.19%
From $1.61 to $3.69 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.88 out of 5 stars

Medical Sector

219th out of 938 stocks

Biological Products, Except Diagnostic Industry

28th out of 154 stocks

KRYS stock logo

About Krystal Biotech Stock (NASDAQ:KRYS)

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

KRYS Stock Price History

KRYS Stock News Headlines

Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
KRYS Apr 2024 180.000 call
KRYS Apr 2024 145.000 put
KRYS Aug 2024 210.000 call
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
KRYS Mar 2024 210.000 call
KRYS May 2024 210.000 call
KRYS May 2024 200.000 put
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
Krystal Biotech Analysts Increase Their Forecasts Following Q4 Results
Q4 2023 Krystal Biotech Inc Earnings Call
Krystal Biotech Shares Climb on Unexpected 4Q Profit
See More Headlines
Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:KRYS
Fax
N/A
Employees
229
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$157.67
High Stock Price Target
$195.00
Low Stock Price Target
$118.00
Potential Upside/Downside
-11.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$10.93 million
Pretax Margin
25.44%

Debt

Sales & Book Value

Annual Sales
$50.70 million
Book Value
$27.60 per share

Miscellaneous

Free Float
23,483,000
Market Cap
$5.06 billion
Optionable
Optionable
Beta
0.86

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

KRYS Stock Analysis - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings
or view top-rated stocks.

What is Krystal Biotech's stock price target for 2024?

9 Wall Street analysts have issued 12 month price targets for Krystal Biotech's stock. Their KRYS share price targets range from $118.00 to $195.00. On average, they anticipate the company's stock price to reach $157.67 in the next twelve months. This suggests that the stock has a possible downside of 11.4%.
View analysts price targets for KRYS
or view top-rated stocks among Wall Street analysts.

How have KRYS shares performed in 2024?

Krystal Biotech's stock was trading at $124.06 at the beginning of the year. Since then, KRYS shares have increased by 43.4% and is now trading at $177.93.
View the best growth stocks for 2024 here
.

When is Krystal Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our KRYS earnings forecast
.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) released its quarterly earnings data on Monday, February, 26th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.82. The business earned $42.14 million during the quarter, compared to analyst estimates of $27.43 million. During the same quarter last year, the firm earned ($1.25) EPS.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

Krystal Biotech (KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.63%), Vanguard Group Inc. (8.61%), Jennison Associates LLC (2.57%), Dimensional Fund Advisors LP (1.95%), Price T Rowe Associates Inc. MD (1.51%) and Price T Rowe Associates Inc. MD (1.51%). Insiders that own company stock include Andrew C Orth, Daniel Janney, Dino A Rossi, Kathryn Romano, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends
.

How do I buy shares of Krystal Biotech?

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KRYS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners